CAMBRIDGE, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will conduct a conference call to discuss the approval of Glatopa™ (glatiramer acetate injection, formerly M356) 20mg/mL, the first substitutable generic for COPAXONE®.
Management will host a conference call today at 1:30 pm ET. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 30313041. A replay of the call will be available approximately two hours after the conclusion of the call and will be accessible through July 16, 2014. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the access code 30313041.
The audio webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Copaxone is a registered trademark of Teva Pharmaceuticals. Glatopa is a trademark of Novartis AG.
CONTACT: Momenta Pharmaceuticals, Inc. email@example.com